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Glycopeptide Resistance in Gram-positive Bacteria 
David C.E. Speller, William A. Lynn+ and Thomas R. Rogers* 
Readers are invited to use this article as a self-assessment 
exercise and to update their knowledge. 
Illustrative case history 
A 20-year-old female presented in 1992 with nephritis 
due to systemic lupus erythematosus. Despite plasma- 
pheresis and immunosuppression she became dialysis- 
dependent. Previous complications included failed 
renal transplantation, recurrent bacterial and viral 
infections and cyclophosphamide-related common 
variable immunodeficiency. 
In late 1994 she was admitted for placement of 
a femoral venous shunt for haemodialysis access. She 
was admitted to a renal unit, which had an ongoing 
outbreak of colonization and infection with glyco- 
peptide-resistant Enterococcus faecium. She had previously 
been admitted to this ward on numerous occasions, and 
multiple courses of antibiotics, including cephalo- 
sporins, ciprofloxacin, gentamicin and vancomycin, 
had been given. At the time of admission she was 
afebrile and generally well and screening swabs showed 
no colonization with E.  faecium. A right femoral vein 
gortex graft was inserted; the operation was com- 
plicated by a small hematoma. Antibiotic prophylaxis 
was given, with intravenous cefuroxime and metro- 
nidazole for 48 hours. O n  post-operative day 5 she 
became febrile, but the surgical wound was clean 
and there was no obvious infective source. The 
peripheral leukocyte count was 6.4 x 109/1 and the 
C-reactive protein 159 mg/l (normal: <I0  mg/l). 
Empiric therapy was commenced with intravenous 
ceftazidime and vancomycin. Her chest X-ray was 
clear, and urine and sputum cultures negative. Blood 
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cultures subsequently grew E.  faecium. A wound swab 
from the right groin also grew E. faecium with 
coliforms. The isolates of E. faecium were resistant to 
ampicillin, vancomycin and teicoplanin (VanA pheno- 
type) and displayed varying sensitivity to gentamicin. 
Her clinical condition failed to respond to the 
treatment and so 72 hours later therapy was begun, 
on a “compassionate use” basis, with quinupristid 
dalfopristin (RP 59500), an unlicensed streptogramin 
antibiotic combination related to pristinamycin, to 
which the isolates of E. faecium were sensitive. 
Despite a reduction in her fever and improvement 
in her general condition she had a persistent in- 
flammatory response, and blood cultures and wound 
swabs repeatedly yielded resistant E. faecium. Ten days 
after treatment with quinupristin/dalfopristin was 
started, the gortex vein graft was surgically removed 
and dialysis was continued via a central venous catheter. 
There was prompt clinical improvement with resolu- 
tion of the bacteremia. Antibiotics were continued for 
a further week with no subsequent recurrence of fever 
or bacteremia. Interestingly, at no time before the initial 
episode of bacteremia had superficial colonisation with 
resistant E. faecium been detected, despite repeated 
investigation of swabs from throat and groin. 
Discussion points 
Glycopeptide resistance in gram-positive cocci has 
emerged as a hospital problem in recent years. The 
multi-resistant enterococcus has been named “the 
nosocomial pathogen of the 1990’s” (1). The correct 
management of such problems has not been established 
but in the USA the Hospital Infection Control 
Practices Advisory Committee has recently issued 
extensive Recommendations (2). 
The Unit 
Glycopeptide-resistant enterococci (GRE) have been 
encountered in renal units and also in hematology, 
oncology and transplant units. Recently there have 
been reports of a particular association with intensive 
care units (3), including childhood intensive care. 
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Admission during an outbreak 
It  does not seem feasible to close units to new 
admissions because of the occurrence of GRE, 
although this would be the usual recommendation in 
the case of other readily transmissible multi-resistant 
pathogens, such as niethicillin-resistant Staphylococcus 
aureus (MRSA). Our policy has been to cohort-nurse 
colonized patients, detected by weekly screening, in 
one area of the ward, and to admit new patients to a 
separate area free from colonized patients. Patients with 
clinical infection, who receive more frequent and closer 
medical and nursing attention, are cared for in a single 
room with full isolation precautions - in the manner 
recommended for both colonized and infected patients 
in the recent Recommendations (2). 
Screening 
Our practice is to screen all patients in affected wards 
a t  weekly intervals with culture of throat and groin 
swabs and, where possible, feces. Direct culture is 
made on blood agar containing 25 mg/l neoniycin 
with application of a paper disc containing 30 p g  
vancomycin. Preliminary enrichment culture in nutri- 
ent broth containing 6 mg/l vancomycin increases the 
yield of positives. Various selective culture systems are 
reconimended in the literature (2). 
Role of previous antibiotic administration 
Data are accumulating to suggest that cephalosporins 
and quinolones select for gram-positive bacteria 
resistant to them, such as enterococci and Clostridium 
dficile. Antibiotic policies in such units need to be 
flexible and applied judiciously, with frequent review 
of the rationale for treatment of individual patients. 
Vancomycin or teicoplanin may be used as part of 
unit policy or invoked to deal with infection by 
emerging gram-positive bacteria. Many outbreaks of 
GRE have followed increased vancomycin use and this 
may be a significant factor for the colonization of 
individual patients; the use of glycopeptides requires to 
be rigorously controlled ( 2 ) .  
Prophylaxis for insertion of a vascular graft 
We advocate narrow-spectrum prophylaxis aimed at 
S. aureus, with an isoxazolyl penicillin, such as 
cloxacillin, possibly with gentamicin. In a unit with 
problems of GRE cephalosporins and glycopeptides 
should be avoided. 
Our recommendation would remain the same in 
a patient (unlike the present case) already known to 
be colonized by GKE. We should wish at  the present 
time to reserve the few investigational agents active 
against such strains, such as quinupristin/dalfopristin, 
for treatment of actual infection, although the suscepti- 
bility of the relevant strain to such agents should be 
determined. 
Importance of the infected graft 
In general, it may be impossible to eradicate infection 
in the presence of a foreign body or a large extra- 
vascular focus with antibiotics. Initial experience with 
quinupristin/dalfopristin bears out this limitation (4). 
General multiple choice questions on glycopeptide resistance in gram-positive bacteria 
In each of the numbered questions at least one and up to$ve Ofthe individual entries are correct. The  answers are on the 
next page. 
1. Glycopeptide (vancomycin or teicoplanin) resistance has been reported and confirmed in: 
a. Norardia asteroides 
b. Pediococcus pentosaceus 
c. Enteroroccus gallinarum 
d. Listeria monocytogenes 
e. Streptococcus pneumoniae. 
a. Vancomycin resistance in Staphylococcus aureus has now been encountered clinically 
b. Teicoplanin resistance is commoner than vancomycin resistance in coagulase- 
c. Among coagulase-negative staphylococci, teicoplanin resistance occurs only 
2. Glycopeptide resistance in Staphylococcus species: 
in the USA and Europe 
negative staphylococci 
in Staphylococcus haemolyticus 
true/false 
true/false 
true/false 
true/false 
true/false 
true/false 
true/false 
true/false 
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d. Laboratory detection of resistance by disc tests is made difficult by poor diffusion 
e. Laboratory detection of teicoplanin resistance is highly dependent on the medium 
characteristics 
used. 
3. Glycopeptide resistance in enterococci: 
a. may be associated with production of novel membrane protein enzymes 
b. may be due to enzymatic destruction of the antibiotic 
c.  may be due to reduced binding of antibiotic to side-chains of cell wall precursors 
d. may be mediated by genes carried on transposons 
e. to teicoplanin is always associated with the vanA gene rather than the vanB gene. 
a. in farm animals 
b. to persist for >3 months in hospital patients 
c. in the feces of hospital staff 
d. in operating theatre air 
e. to persist for >3 days in the hospital environment. 
4. Glycopeptide-resistant enterococci have been detected and reported 
5. Characteristic clinical associations reported: 
a. 
b. 
C. 
d. 
e. 
Vancomycin-resistant enterococci - endocarditis on natural heart valves 
Vancomycin-resistant enterococci - persistent bacteria without endocardltis 
or extravascular focus 
Vancomycin-resistant Leuconostoc species - bacteremia associated with 
colonization of intravascular cannula 
Vancomycin-resistant lactobacillus endocarditis - relapse after treatment with 
penicillin alone 
Teicoplanin-resistant staphylococci - results of treatment poorly correlated with 
in vitro susceptibility test results. 
6. Ampicillin treatment of infections by vancomycin-resistant enterococci: 
a. High-level (MIC >2000 mg/l) resistance to gentamicin and streptomycin 
b. Ampicillin alone in high doses may succeed in endocarditis 
c. Ampicillin resistance may occur by p-lactamase production 
d. Addition of sulbactam restores sensitivity to all ampicillin-resistant strains 
e. Ampicillin and vancomycin may show synergism against ampicillin- and 
implies absence of synergism with all available aminoglycosides 
vancomycin-resistant strains. 
7. Developments in the following antimicrobial groups show promise for the future 
treatment of infections by multi-resistant enterococci: 
a. glycopeptides 
b. cephalosporins 
c. aminoglycosides 
d. pristinamycins 
e. quinolones. 
truelfalse 
truelfalse 
truelfalse 
truelfalse 
truelfalse 
true/false 
truelfalse 
truelfalse 
true/false 
truelfalse 
true/false 
truelfalse 
true/false 
true/false 
true/false 
true/false 
true/false 
truelfalse 
true/false 
true/false 
true/false 
truelfalse 
true/false. 
truelfalse 
truelfalse 
truelfalse 
truelfalse 
Commentary on multiple choice questions 
Question 1 
Resistance to vancomycin, in the gram-positive species 
susceptible to it, first appeared among enterococci in 
the 1980s, when a nosocomial outbreak of infection 
by vancomycin-resistant enterococci was reported (5). 
Since that time sporadic cases and clusters have been 
reported from Europe and the USA. High- and low- 
level resistance has been encountered in Enterococcus 
Answers to multiple choice questions 
QZ a. true; b. true; c. true; d. false; e. false 
4 2  a. false; b. true; c. false; d. true; e. true 
4 3  a. true; b. false; c. true; d. true; e. false 
4 4  a. true; b. true; c. true; d. false; e. true 
4 5  a. true; b. true; c. true; d. true; e. true 
Q6 a. true; b. true; c. true; d. false; e. true 
4 7  a. true; b. false; c. false; d. true; e. true 
S p e l l e r ,  L y n n ,  R o g e r s ,  G l y c o p e p t i d e  R e s i s t a n c e  i n  G r a m - p o s i t i v e  B a c t e r i a  57 
faecium and Enterococcus faecalis, while low-level con- 
stitutive resistance is a characteristic of Enterococcus 
gallinarum and other species that are less frequently 
encountered in human infection (6). 
Resistance to glycopeptides is common in lactic 
acid bacteria, such as Pediococcus, Leuconostoc and 
Lactobacillus species (7). These have been noted more 
frequently as opportunistic pathogens, particularly 
following glycopeptide administration. In the case of 
other gram-positive bacteria that are often resistant to 
glycopeptides, such as Nocardia spp. and Erysipelothrix 
rhusiopathiae, administration of glycopeptides does not 
usually arise, either as a predisposing factor or as a 
therapeutic option. 
A fear is that the genetic material mediating resis- 
tance to the glycopeptides may be transferred to species 
which are sensitive at present, such as Streptococcus 
pneumoniae. 
Question 2 
I t  is particularly worrying that vancomycin resistance 
can be transferred (in the laboratory) from an entero- 
coccus to Staphylococcus aureus (8), but thus far no 
confirmed report of resistance in clinical S. aureus 
isolates has been published. Low-level resistance to 
teicoplanin, however, has been reported (9). 
In coagulase-negative staphylococci teicoplanin 
resistance dominates (lo), although vancomycin resis- 
tance has been encountered (11). The earlier reports of 
high-level teicoplanin resistance concerned Staphylo- 
coccus haernolyticus, but this phenomenon is also seen in 
Staphylococcus epiderrnidis, Staphylococcus warneri, Staphy- 
lococcus horninis and Staphylococcus xylosus. 
Exercises comparing the performance of labora- 
tories in the detection of glycopeptide resistance, in 
Europe and in the USA, have shown success in the 
detection of high-level vancomycin resistance in 
enterococci, but poor results with strains showing 
resistance at a lower level (12, 13). Several factors con- 
tribute to inconsistent laboratory reporting. There are 
discrepancies between the interpretive breakpoints 
recommended in different countries (1 4, 15). The 
diffusion characteristics of the large molecules make the 
zones of inhibition in disc tests very small and less easy 
to interpret. In addition, very different MIC values of 
teicoplanin may be obtained with various media, with 
and without the addition of blood, and with changes 
in inoculum (1 6). 
Question 3 
There is no evidence of destruction of glycopeptides by 
resistant strains of E. faecium and E .  faecalis (17). Such 
strains have been shown to synthesize novel membrane 
proteins, which in some cases have been shown to 
possess D-ala-D-ala ligase activity and to produce 
different peptide side-chains on the cell wall com- 
ponents. These will not bind glycopeptides and, even 
in their presence, can link up to give the strengthening 
cross-linking structure to the bacterial cell wall (18). 
The resistant enterococci first described showed 
inducible high-level resistance to vancomycin and also 
resistance to teicoplanin: the “VanA phenotype”. 
Other strains were encountered, however, showing 
lower levels of inducible vancomycin resistance and 
sensitivity to teicoplanin: the “VanB phenotype” 
(“VanC” describes the low-level constitutive resistance 
to vancomycin with sensitivity to teicoplanin seen in 
E .  gallinarum and some other species). The corres- 
ponding genes have been identified. More recently 
strains possessing the vanB gene, rather than the vanA 
gene, have been described with high-level vancomycin 
resistance and resistance to teicoplanin (1 9). 
VanA glycopeptide resistance was early demon- 
strated to be plasmid-borne and transferable. Mobility 
of this genetic material is enhanced by its occurrence 
as a transposon. The  resistance transposon T n  I546 
carries a complex of genes encoding glycopeptide 
resistance (including vanA) and its regulation (20). 
Question 4 
Glycopeptide-resistant enterococci were first encoun- 
tered in hospitals, and it is believed that antibiotic 
pressure, first of cephalosporins (to which enterococci 
are intrinsically resistant) and subsequently of glyco- 
peptides, is important in their emergence. Never- 
theless, glycopeptide-resistant enterococci have been 
discovered in the gastro-intestinal tracts of patients in 
the community (21), in farm animals and in poultry for 
sale (22). 
The carriage rate of patients in intensive care, renal 
and hematology units may be high, and the glyco- 
peptide-resistant enterococci may persist for long 
periods (23). The factors affecting patient-to-patient 
spread during outbreaks are still obscure. Staff may 
become colonized (24) but this is not a consistent 
finding. Likewise, contamination of the immediate 
environment of patients and transient contamination 
of staff hands have appeared to be significant factors 
in some outbreaks (25, 26) but not in others. 
Question 5 
Most of the species of glycopeptide-resistant gram- 
positive bacteria under discussion characteristically act 
as opportunistic pathogens in impaired hospital 
patients. Even when they are isolated from deep 
specimens their clinical significance may be difficult to 
assess. Bacteremia may persist without a defined focus 
and with seemingly little deleterious effect on the 
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patient (27). Removal of an intravascular cannula may 
be sufficient to cure the bacteraemia (28). Assessment 
of clinical results assisted the National Committee for 
Clinical Laboratory Standards in establishing break- 
points for teicoplanin (1 4), but many investigators have 
commented on the poor correlation between in vitro 
results and clinical outcome (29). Endocarditis provides 
a clear test of the power of an antibiotic regimen. 
In the case of endocarditis caused by the lactic acid 
bacteria, definitive advice on treatment cannot be 
given, but it is clear that a bactericidal synergistic 
combination should be used (30). 
Question 6 
Unfortunately, glycopeptide-resistant strains of E. 
faecium are often resistant to 6-lactams and, at  high- 
level, to aminoglycosides. Gentamicin is the amino- 
glycoside usually tested. If there is high-level resistance 
to this agent, it is worthwhile to test streptomycin. 
High-level resistance to both implies that no clini- 
cally available aminoglycoside will give satisfactory 
synergy (31). In these circumstances, apparent sensitivity 
to amikacin does not denote sufficient activity to 
give synergy. If an aminoglycoside-resistant strain is 
ampicillin-sensitive this agent alone in high doses is the 
current recommendation in endocarditis (31). Some- 
times it is possible to demonstrate, in strains resistant to 
both p-lactams and glycopeptides, a synergistic activity 
of a combination of these agents, but this is not a 
consistent finding (32). 
Resistance caused by p-lactamase production 
has been described, especially in the USA, and the 
P-lactamase is susceptible to clavulanate and to sul- 
bactam (33), but most p-lactam-resistant strains are 
resistant by a different mechanism: modification of 
penicillin-binding proteins. 
Question 7 
Because of these increasing therapeutic problems, 
there is a need to search for new active compounds. 
Investigation of p-lactams and aminoglycosides has 
not been fruitful. The clinical activity of newer 
peptides, such as daptomycin, has been disappointing 
thus far, although further compounds with much 
greater activity are under development and appear 
promising (34, 35). New fluoroquinolones, with in- 
creased activity against gram-positive bacteria, are 
being developed (36) and offer some promise although 
they require clinical trial in these infections. The 
injectable pristinamycin combination, quinupristin/ 
dalfopristin has been used with success against some 
infections by multi-resistant enterococci (37). This is 
more active against E.faecium than against E.faecalis and 
appears to have almost no bactericidal activity against 
enterococci. Bacteriostatic activity is also shown by the 
glycylcyclines (tetracycline derivatives) (38). 
Despite the comparatively non-pathogenic char- 
acter of many of the species that show glycopeptide 
resistance, the need to treat infections caused by them 
is becoming more frequent. The ready transmissibility 
of the underlying genetic material poses a serious threat 
to our future use of antibiotics. 
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